The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

It takes 10–15 years and hundreds of millions of dollars for a pharmaceutical company to navigate the Food and Drug ...

Earlier this year, the FDA approved 2 new indications for Aquaflor. According to Merck, the supplemental approval increased ...

Some pet owners want a recall of a new arthritis drug for cats after their animals died, some in horrific ways, just days ...

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...

Revumenib is now an FDA-approved treatment for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute ...

The U.S. FDA’s new draft guidance for the voluntary incorporation of patient preference information (PPI) in device development says that PPI would be included in product labels for cleared or ...

The U.S. Food and Drug Administration has approved Journey Medical's drug for the treatment of a long-term skin condition ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

NeurAxis (NYSE:NRXS) announced today that the FDA granted an expanded 510(k) clearance for its IB-Stim non-implanted nerve ...